Free Newsletter
Otsuka puts off broadening use of Abilify
Free newsletter via e-mail
Tools
Otsuka Pharmaceutical yanked its European application for broader use of Abilify; it had asked the EMEA for permission to market the antipsychotic drug as a treatment for depression. Report
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
